Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.
Abstract: Disclosed are a series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
Type:
Grant
Filed:
September 2, 2011
Date of Patent:
May 12, 2015
Assignee:
UCB Pharma S.A.
Inventors:
Andrew Harry Parton, Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Daniel James Ford, Richard Jeremy Franklin, Judi Charlotte Neuss, Joanna Rachel Quincey, Jackalyn Hinkins
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
Type:
Grant
Filed:
November 6, 2012
Date of Patent:
April 21, 2015
Assignee:
UCB Pharma S.A.
Inventors:
David G. Winkler, Jiye Shi, John Latham
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
Type:
Grant
Filed:
November 6, 2012
Date of Patent:
March 31, 2015
Assignee:
UCB Pharma S.A.
Inventors:
David G. Winkler, Jiye Shi, John Latham
Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
Type:
Grant
Filed:
May 23, 2014
Date of Patent:
March 24, 2015
Assignee:
UCB Pharma S.A.
Inventors:
Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
Abstract: The present invention relates to the manufacture of recombinant antibodies of therapeutic quality. In particular, the invention relates to methods for increasing the yield of functional antibody from large scale fermentations whereby a cultured host cell sample is subjected to a non-lysing treatment.
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a mutant spr protein and wherein the cell comprises a non-recombinant wild-type chromosomal Tsp gene.
Abstract: The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell.
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
Abstract: A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
Type:
Grant
Filed:
November 11, 2010
Date of Patent:
February 17, 2015
Assignee:
UCB Pharma S.A.
Inventors:
Gilles Raphy, Roland Bürli, Alan Findlay Haughan
Abstract: The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
Abstract: The present invention relates to optically enriched or substantially optically pure 4-substituted-pyrrolidin-2-ones of formula (III), and their uses for the synthesis of 2-oxo-pyrrolidin-1-yl derivatives.
Type:
Grant
Filed:
September 12, 2006
Date of Patent:
February 17, 2015
Assignee:
UCB Pharma S.A.
Inventors:
Celal Ates, Francoise Lurquin, Yannick Quesnel, Arnaud Schule
Abstract: Systems, devices, and methods are provided for providing safe syringe assemblies for injections. The syringe assemblies include a shielding mechanism that covers a syringe needle after an injection is delivered, thereby reducing the risk of a subsequent accidental stab from the needle. The shielding mechanism has a pre-injection configuration in which the needle extends beyond the housing and a post-injection configuration in which at least one component of the syringe assembly covers the needle. In some implementations, the syringe assembly includes a lock that inhibits the assembly from returning to the pre-injection configuration once an injection is delivered. The syringe assemblies may also include a bevel orientation mechanism that allows a user to align a needle bevel to accurately insert a needle for injection.
Type:
Grant
Filed:
June 25, 2012
Date of Patent:
February 3, 2015
Assignee:
UCB Pharma S.A.
Inventors:
Anthony Torris, Alistair Bramley, Dan Formosa, Eric Freitag
Abstract: The autoinjector systems disclosed herein provide in part devices for allowing patients with reduced joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a housing, a syringe assembly slidably mounted on the housing, and a needle cap releasably engaged to the housing, where the cap includes a protruding pocket for receiving a needle cap remover.
Type:
Grant
Filed:
July 20, 2009
Date of Patent:
February 3, 2015
Assignee:
UCB Pharma, S.A.
Inventors:
Martin John McLoughlin, Alex Lee, Dan Formosa, Steven Vordenberg, Joern Vicari, Eric Freitag, Boris Kontorvich
Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
Type:
Grant
Filed:
October 27, 2010
Date of Patent:
January 6, 2015
Assignee:
UCB Pharma S.A.
Inventors:
Karen Margrete Miller, Marc Roger De Ryck, Christian Gilbert J. Wolff, Alastair David Griffiths Lawson, Helene Margaret Finney, Terence Seward Baker
Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.
Inventors:
Martin John McLoughlin, Michael James David Heald, Darrell P. Morgan, Kevin Richard Lozeau, Agnete Enga, Daniel Formosa, Michael Schumann, Vincent Faivre d'Arcier
Inventors:
Martin John McLoughlin, Michael James David Heald, Darrell P. Morgan, Kevin Richard Lozeau, Agnete Enga, Daniel Formosa, Michael Schumann, Vincent Faivre d'Arcier, Ilario Melzi, Stefan Verlaak, Tatiana Palombi
Inventors:
Martin John McLoughlin, Michael James David Heald, Darrell P. Morgan, Kevin Richard Lozeau, Agnete Enga, Daniel Formosa, Michael Schumann, Vincent Faivre d'Arcier, Ilario Melzi, Stefan Verlaak, Tatiana Palombi